Dosimetry of 177Lu-DOTATOC first circle treatment in patients with advanced metastatic neuroendocrine tumors: A pilot study in China

Appl Radiat Isot. 2022 Jan:179:109975. doi: 10.1016/j.apradiso.2021.109975. Epub 2021 Oct 2.

Abstract

First cycle dosimetry calculation of 177Lu-DOTATOC (single activity:1.59-3.49 GBq) was carried out in eight patients with advanced neuroendocrine tumors (NETs) who underwent whole-body planar (0.5, 24, 48, 72 h) and SPECT/CT scans (24 h). Focal uptake of 177Lu-DOTATOC was found in primary and metastatic tumors. Organs with the highest absorbed doses per injected activity were tumors (1.293 ± 0.862 mGy/MBq) and spleen (0.461 ± 0.408 mGy/MBq), while low absorbed doses were observed in kidneys (0.384 ± 0.112 mGy/MBq) and bone marrow (0.0297 ± 0.0123 mGy/MBq). 177Lu-DOTATOC is safe, well-tolerated and appropriate in Chinese NETs patients for PRRT.

Keywords: (177)Lu-DOTATOC; Dosimetry; Neuroendocrine tumor; PRRT.

MeSH terms

  • Adult
  • China
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Metastasis / diagnostic imaging
  • Neoplasm Metastasis / radiotherapy*
  • Neuroendocrine Tumors / diagnostic imaging
  • Neuroendocrine Tumors / pathology
  • Neuroendocrine Tumors / radiotherapy*
  • Octreotide / analogs & derivatives*
  • Octreotide / pharmacokinetics
  • Octreotide / therapeutic use
  • Organometallic Compounds / pharmacokinetics
  • Organometallic Compounds / therapeutic use*
  • Pilot Projects
  • Positron Emission Tomography Computed Tomography
  • Radiation Dosage*
  • Radiometry / methods*
  • Reproducibility of Results
  • Single Photon Emission Computed Tomography Computed Tomography

Substances

  • Organometallic Compounds
  • edotreotide lutetium LU-177
  • Octreotide